Please assess the completion status of the following clinical trial:

Trial Title: Proteasome Inhibitor PS-341 Relapsed or Refractory B Cell Lymphomas Previously Treated With Chemotherapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
INCLUSION:~* Relapsed or Refractory B cell lymphoma.~* Zubrod status \</= 3.~* Measurable disease.~* No anti-cancer treatment within past 3 weeks.~* ANC \>= 1500/uL, Plt \>/= 50,000, Bilirubin \<2 mg/dL, SGPT \<2.5xULN, creatinine \<2. Patients with ANC\>/1000, PLT\>/30000 will be eligible if due to massive splenomegaly and/or BM involvement.~* HIV negative.~* No active CNS lymphoma.~* No serious intercurrent illness, active infections or cancer except basal cell carcinoma of the skin or in situ cervical carcinoma.~* Not eligible for treatment of a higher priority. Patients may be entered before BMT.~* No pregnancy \& age bearing females must be practicing adequate contraception.~* Age \> 16.~EXCLUSION:~* Patients with platelets \<30x10(9)/L within 14 days before enrollment.~* Patients with ANC\<1.0 x10(9)/L within 14 days before enrollment.~* Patients with peripheral neuropathy \>/= grade 3 within 14 days before enrollment.

- Gender: ALL
- Minimum Age: 17 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (mantle-cell lymphoma) (Type: EXPERIMENTAL): None
- Arm B (other B-cell lymphomas) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).